Albert Labs

Albert Labs

Innovative mental health medicines for patients with unmet needs

Founded 2020

London, United Kingdom 8 employees Post-IPO Debt Total: $830.00K Biotechnology, Health and Wellness +1

Albert Labs is a bio-pharmaceutical company founded in 2020 with a focus on developing innovative mental health medicines to address the unmet needs of patients. The company is pursuing licensing approval for active compounds from natural sources, aiming to provide access to effective prescription medicines for people suffering from mental health disorders. The team of drug development experts at Albert Labs leverages advanced culture technology and extraction methods to produce unique and effective natural medicines. The company's approach involves developing clinical solutions through an approved, fast track regulatory pathway with a focus on Real World Evidence (RWE) studies. This approach has been increasingly recognized as a valuable clinical access route, particularly in oncology and in the successful development of COVID-19 vaccines. Albert Labs collaborates with research institutions, hospital centers, and government agencies to utilize existing clinical infrastructure and improve patient access to treatment. Their first drug target, KRN-101, is aimed at providing a potential solution for cancer-related anxiety, addressing a market of over 15 million people with an estimated 1 million new sufferers each year. The company is headquartered in the United Kingdom and has recently secured a $830.00K Post-IPO Debt investment at 23 March 2023 from Cantheon Capital. Albert Labs operates within the Biotechnology and Pharmaceutical industries, positioning itself as a promising player in the mental health pharmaceutical sector.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	$830.00K	1	Cantheon Capital	23 Mar 2023

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Debt

$830.00K

Cantheon Capital

23 Mar 2023

FAQ About Albert Labs

Innovative mental health medicines for patients with unmet needs

Albert Labs was founded in 2020.

Albert Labs is headquartered in London, United Kingdom.

Albert Labs operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceutical, mental health, drug development and clinical solutions.

Albert Labs has approximately 8 employees.

Albert Labs has completed 1 funding round, raising a total of $830.00K. The latest funding stage is Post-IPO Debt.

Top alternatives and competitors to Albert Labs include Emyria (ASX:EMD), Cybin Inc, Tetralogic Pharmaceuticals, Courage Therapeutics, NERx Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Albert Labs and Emyria (ASX:EMD) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Albert Labs

Funding Rounds & Investors (1)

Albert Labs Alternatives & Competitors

FAQ About Albert Labs